$g(v)-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
申请人:ONO PHARMACEUTICAL CO., LTD.
公开号:EP1114816A1
公开(公告)日:2001-07-11
An ω-substituted phenyl-prostaglandin derivative of formula (I), a process for the preparation thereof, a medicament comprising it as active ingredient (all symbols have the same meaning as described in the specification).
The compounds of the formula (I) bind strongly on PGE2 receptor (especially subtype EP4) and therefore are useful for the prophylaxis and/or treatment of immune diseases (autoimmune diseases (amyotrophic lateral sclerosis (ALS) etc.), post-transplantation graft rejection, etc.), asthma, abnormal bone formation, neurocyte death, pulmopathy, hepatopathy, etc. They are also related to sleeping disorders and platelet coagulations, and therefore they are also applicable to these diseases.
一种式(I)的ω-取代苯基-前列腺素衍生物,其制备方法,一种以其为活性成分的药物(所有符号的含义与说明书中描述的相同)。
式(I)化合物与 PGE2 受体(尤其是亚型 EP4)结合力强,因此可用于预防和/或治疗免疫性疾病(自身免疫性疾病(肌萎缩性脊髓侧索硬化症(ALS)等)、移植后移植物排斥等)、哮喘、骨形成异常、神经细胞死亡、肺病、肝病等。它们还与睡眠障碍和血小板凝结有关,因此也适用于这些疾病。